586 related articles for article (PubMed ID: 25331092)
21. Inhaled powder formulation of naked siRNA using spray drying technology with l-leucine as dispersion enhancer.
Chow MYT; Qiu Y; Lo FFK; Lin HHS; Chan HK; Kwok PCL; Lam JKW
Int J Pharm; 2017 Sep; 530(1-2):40-52. PubMed ID: 28720537
[TBL] [Abstract][Full Text] [Related]
22. Aerosolization characteristics of dry powder inhaler formulations for the excipient enhanced growth (EEG) application: effect of spray drying process conditions on aerosol performance.
Son YJ; Worth Longest P; Hindle M
Int J Pharm; 2013 Feb; 443(1-2):137-45. PubMed ID: 23313343
[TBL] [Abstract][Full Text] [Related]
23. Co-spray dried carbohydrate microparticles: crystallisation delay/inhibition and improved aerosolization characteristics through the incorporation of hydroxypropyl-β-cyclodextrin with amorphous raffinose or trehalose.
Amaro MI; Tajber L; Corrigan OI; Healy AM
Pharm Res; 2015 Jan; 32(1):180-95. PubMed ID: 25074469
[TBL] [Abstract][Full Text] [Related]
24. Dry powder inhalers of gentamicin and leucine: formulation parameters, aerosol performance and in vitro toxicity on CuFi1 cells.
Aquino RP; Prota L; Auriemma G; Santoro A; Mencherini T; Colombo G; Russo P
Int J Pharm; 2012 Apr; 426(1-2):100-107. PubMed ID: 22301426
[TBL] [Abstract][Full Text] [Related]
25. D-leucine microparticles as an excipient to improve the aerosolization performances of dry powders for inhalation.
Schoubben A; Vivani R; Paolantoni M; Perinelli DR; Gioiello A; Macchiarulo A; Ricci M
Eur J Pharm Sci; 2019 Mar; 130():54-64. PubMed ID: 30677523
[TBL] [Abstract][Full Text] [Related]
26. Effect of pH and leucine concentration on aerosolization properties of carrier-free formulations of levofloxacin.
Barazesh A; Gilani K; Rouini M; Barghi MA
Eur J Pharm Sci; 2018 Jun; 118():13-23. PubMed ID: 29505814
[TBL] [Abstract][Full Text] [Related]
27. The effect of metal salts on aerosol performance of spray dried carrier-free formulations of levofloxacin.
Barazesh A; Gilani K; Rouini M; Barghi MA
Daru; 2020 Jun; 28(1):75-85. PubMed ID: 31808069
[TBL] [Abstract][Full Text] [Related]
28. Effects of formulation and operating variables on zanamivir dry powder inhalation characteristics and aerosolization performance.
Yang Y; Yang Z; Ren Y; Mei X
Drug Deliv; 2014 Sep; 21(6):480-6. PubMed ID: 24491208
[TBL] [Abstract][Full Text] [Related]
29. Dry powder inhaler formulation of high-payload antibiotic nanoparticle complex intended for bronchiectasis therapy: Spray drying versus spray freeze drying preparation.
Yu H; Teo J; Chew JW; Hadinoto K
Int J Pharm; 2016 Feb; 499(1-2):38-46. PubMed ID: 26757148
[TBL] [Abstract][Full Text] [Related]
30. Design, characterization, and aerosol dispersion performance modeling of advanced co-spray dried antibiotics with mannitol as respirable microparticles/nanoparticles for targeted pulmonary delivery as dry powder inhalers.
Li X; Vogt FG; Hayes D; Mansour HM
J Pharm Sci; 2014 Sep; 103(9):2937-2949. PubMed ID: 24740732
[TBL] [Abstract][Full Text] [Related]
31. Design, physicochemical characterization, and optimization of organic solution advanced spray-dried inhalable dipalmitoylphosphatidylcholine (DPPC) and dipalmitoylphosphatidylethanolamine poly(ethylene glycol) (DPPE-PEG) microparticles and nanoparticles for targeted respiratory nanomedicine delivery as dry powder inhalation aerosols.
Meenach SA; Vogt FG; Anderson KW; Hilt JZ; McGarry RC; Mansour HM
Int J Nanomedicine; 2013; 8():275-93. PubMed ID: 23355776
[TBL] [Abstract][Full Text] [Related]
32. Powder, capsule and device: An imperative ménage à trois for respirable dry powders.
Schoubben A; Blasi P; Giontella A; Giovagnoli S; Ricci M
Int J Pharm; 2015 Oct; 494(1):40-8. PubMed ID: 26255220
[TBL] [Abstract][Full Text] [Related]
33. The influence of formulation components on the aerosolisation properties of spray-dried powders.
Rabbani NR; Seville PC
J Control Release; 2005 Dec; 110(1):130-40. PubMed ID: 16226334
[TBL] [Abstract][Full Text] [Related]
34. Triple combination dry powder formulation of pretomanid, moxifloxacin, and pyrazinamide for treatment of multidrug-resistant tuberculosis.
Fan C; Eedara BB; Sinha S; Uddin MKM; Doyle C; Banu S; Das SC
Int J Pharm; 2024 Apr; 654():123984. PubMed ID: 38461874
[TBL] [Abstract][Full Text] [Related]
35. Impact of Solid-State Properties on the Aerosolization Performance of Spray-Dried Curcumin Powders.
Zhang Q; Li Y; Li L; Cheng Y; Yu F; Li R; Hou S
AAPS PharmSciTech; 2023 Mar; 24(3):78. PubMed ID: 36918500
[TBL] [Abstract][Full Text] [Related]
36. Development and characterization of a spray-dried inhalable ciprofloxacin-quercetin co-amorphous system.
Alhajj N; O'Reilly NJ; Cathcart H
Int J Pharm; 2022 Apr; 618():121657. PubMed ID: 35288220
[TBL] [Abstract][Full Text] [Related]
37. Physicochemical characterization and aerosol dispersion performance of organic solution advanced spray-dried microparticulate/nanoparticulate antibiotic dry powders of tobramycin and azithromycin for pulmonary inhalation aerosol delivery.
Li X; Vogt FG; Hayes D; Mansour HM
Eur J Pharm Sci; 2014 Feb; 52():191-205. PubMed ID: 24215736
[TBL] [Abstract][Full Text] [Related]
38. The use of hydrophobic amino acids in protecting spray dried trehalose formulations against moisture-induced changes.
Mah PT; O'Connell P; Focaroli S; Lundy R; O'Mahony TF; Hastedt JE; Gitlin I; Oscarson S; Fahy JV; Healy AM
Eur J Pharm Biopharm; 2019 Nov; 144():139-153. PubMed ID: 31536784
[TBL] [Abstract][Full Text] [Related]
39. Formulation and characterization of spray-dried powders containing nanoparticles for aerosol delivery to the lung.
Sham JO; Zhang Y; Finlay WH; Roa WH; Löbenberg R
Int J Pharm; 2004 Jan; 269(2):457-67. PubMed ID: 14706257
[TBL] [Abstract][Full Text] [Related]
40. Relationship between surface concentration of L-leucine and bulk powder properties in spray dried formulations.
Mangal S; Meiser F; Tan G; Gengenbach T; Denman J; Rowles MR; Larson I; Morton DA
Eur J Pharm Biopharm; 2015 Aug; 94():160-9. PubMed ID: 26007290
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]